JUNS - Latest News

Jupiter Neurosciences, Inc. (JUNS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $2.0M. Beta to the broader market is 1.96.

The article list below shows the most recent JUNS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent JUNS Headlines

Jupiter Neurosciences announces pricing of $2M registered direct offering

https://thefly.com - Aug 21, 2026

Jupiter Neurosciences announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a r

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

globenewswire.com - Aug 21, 2026

New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc.

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

benzinga.com - Aug 21, 2026

Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc.

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

globenewswire.com - Aug 5, 2026

Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

globenewswire.com - Jul 21, 2026

Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase

How News Affects JUNS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track JUNS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked JUNS news questions

What is the latest JUNS news headline?

The most recent JUNS headline (Aug 21, 2026) is "Jupiter Neurosciences announces pricing of $2M registered direct offering". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the JUNS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What JUNS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual JUNS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.